Skip to main content

Update on AGM Procedure

LONDON, April 08, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, provides an update on its upcoming Annual General Meeting (“AGM”), scheduled to be held at the offices of Shakespeare Martineau at 60 Gracechurch Street, London EC3V 0HR, United Kingdom at 10.30 a.m. on April 16, 2020.
The Company currently plans to hold its AGM as scheduled, however given the UK Government’s present restrictions on public gatherings of more than two people, the Board requests shareholders to vote by proxy rather than attend the AGM in person. Any shareholders seeking to attend the AGM in person will be refused entry.By way of reminder, the deadline for delivery of completed proxy forms by holders of the Company’s ordinary shares is 10.30 a.m. on April 14, 2020. The equivalent deadline for proxy voting by holders of the Company’s American Depository Shares is 10 a.m. on April 9, 2020.Verona Pharma continues to review the UK Government’s restrictions and recommends that shareholders monitor the Company’s website and announcements for any updates in relation to the AGM. In the event that its AGM arrangements have to change, the Company will issue a further communication via a regulatory information service.A copy of our AGM Notice and Annual Report are available on the Company’s website within the Investors section, www.veronapharma.com.For further information, please contact:

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.